Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1

Interventions

Oxaliplatin 112Fluorouracil 104Leucovorin 91Irinotecan 91Capecitabine 59Bevacizumab 58Cetuximab 46Folfox protocol 28Colonoscopy 24Panitumumab 19Chemotherapy, Adjuvant 19Blood Specimen Collection 19Drug Therapy 18Nivolumab 17Magnetic Resonance Spectroscopy 17Radiotherapy 16Exercise 16Early Intervention, Educational 16Surveys and Questionnaires 15Laparoscopy 15Surgical Procedures, Operative 13Floxuridine 13Biopsy 13trifluridine tipiracil drug combination 12pembrolizumab 12XELOX 12Neoadjuvant Therapy 11Methods 11Immunohistochemistry 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colonic Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡